| UHC Commercial Medical & Drug | Obstructive and Central Sleep Apnea Treatment – Commercial and Individual Exchange Medical Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Oncology Medication Clinical Coverage – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Ophthalmologic Vascular Endothelial Growth Factor (VEGF) Inhibitors – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Outpatient Cardiology Procedures for EviCore Arrangement (for Oxford Only) – Oxford Medical Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Outpatient Radiology Procedures for EviCore Arrangement (for Oxford Only) – Oxford Medical Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Papzimeos™ (Zopapogene Imadenovec-Drba) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Preventive Care Services – Commercial and Individual Exchange Medical Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Provider Administered Drugs – Site of Care – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Repository Corticotropin Injections – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) – Commercial Medical Benefit Drug Policy | 2026-04-01 |